Value of in Vitro Diagnostic IVD Tests in Health Society and Economy in Portugal
Author(s)
Paula Rodrigues, BSc1, Sílvia Mota, BSc1, Carolina Amaral, BSc1, Bruno Garganta, BS2, Carlos Catalão, BS3, Liliana de Almeida, BS3, Inês Teixeira, MSc4, Paula Costa, BE5, Paulo Dias, BE4.
1ANTARES Consulting, Lisboa, Portugal, 2Werfen, Lisboa, Portugal, 3Roche Sistemas de Diagnósticos, Lisboa, Portugal, 4Portuguese Pharmaceutical Industry Association - APIFARMA, Lisboa, Portugal, 5Portuguese Pharmaceutical Industry Association - APIFARMA / Comprehensive Health Research Centre - University of Évora, Lisboa, Portugal.
1ANTARES Consulting, Lisboa, Portugal, 2Werfen, Lisboa, Portugal, 3Roche Sistemas de Diagnósticos, Lisboa, Portugal, 4Portuguese Pharmaceutical Industry Association - APIFARMA, Lisboa, Portugal, 5Portuguese Pharmaceutical Industry Association - APIFARMA / Comprehensive Health Research Centre - University of Évora, Lisboa, Portugal.
OBJECTIVES: This study aims to aggregate and generate evidence on the contribution of In Vitro Diagnostic (IVD) Tests to Health, Society and Economy, based on investment at different stages of the diagnostic or follow-up, on a specific period, for a set of pathologies. Four pathologies with high or increasing incidence and prevalence were selected: COVID-19, diabetes, heart failure, and lung cancer.
METHODS: The Social Return on Investment (SROI) was the methodology used to estimate the economic and social return obtained for each euro invested on an annual basis. A literature review was conducted, and the information and perspectives of various stakeholders were also supported by interviews and focus groups. An impact map was developed, outlining inputs, outputs, and outcomes, followed by the valuation of impacts on individuals, family/caregivers, healthcare professionals, healthcare providers, the healthcare system and the society. A conservative approach was consistently adopted in estimating quantities and monetary valuations.
RESULTS: A social return of €8.2 for every €1 invested in PCR tests and professional Ag-RDTs was estimated, highlighting their importance in the diagnosis and control of COVID-19 transmission; for every €1 invested in 2019 in tests for monitoring blood glucose levels (HbA1c and self-monitoring of blood glucose) in people with diabetes, a social return of €6 was generated; a €12.6 SROI was estimated for the utilization of B-type natriuretic peptide tests in primary healthcare for people suspected of having heart failure; and a €14.9 SROI was estimated for molecular testing, specifically next-generation sequencing (NGS) in patients with new cases of stage IV adenocarcinoma.
CONCLUSIONS: The case studies demonstrated an economic and social return of between six to fifteen times the value of the investment. The four cases serve as illustrative examples of the IVD tests use and benefits, representing a sample of their broader application.
METHODS: The Social Return on Investment (SROI) was the methodology used to estimate the economic and social return obtained for each euro invested on an annual basis. A literature review was conducted, and the information and perspectives of various stakeholders were also supported by interviews and focus groups. An impact map was developed, outlining inputs, outputs, and outcomes, followed by the valuation of impacts on individuals, family/caregivers, healthcare professionals, healthcare providers, the healthcare system and the society. A conservative approach was consistently adopted in estimating quantities and monetary valuations.
RESULTS: A social return of €8.2 for every €1 invested in PCR tests and professional Ag-RDTs was estimated, highlighting their importance in the diagnosis and control of COVID-19 transmission; for every €1 invested in 2019 in tests for monitoring blood glucose levels (HbA1c and self-monitoring of blood glucose) in people with diabetes, a social return of €6 was generated; a €12.6 SROI was estimated for the utilization of B-type natriuretic peptide tests in primary healthcare for people suspected of having heart failure; and a €14.9 SROI was estimated for molecular testing, specifically next-generation sequencing (NGS) in patients with new cases of stage IV adenocarcinoma.
CONCLUSIONS: The case studies demonstrated an economic and social return of between six to fifteen times the value of the investment. The four cases serve as illustrative examples of the IVD tests use and benefits, representing a sample of their broader application.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
MT46
Topic
Medical Technologies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Diabetes/Endocrine/Metabolic Disorders (including obesity), Infectious Disease (non-vaccine), No Additional Disease & Conditions/Specialized Treatment Areas, Oncology